People suffering from type 2 diabetes not always manage to support normal level Glucose in the blood through diet and physical exertion. Therefore, some diabetics have to use hypoglycemic agents, in particular Glideyab.

This medication helps stabilize blood glucose levels and increase the effectiveness of diet and therapy if diabetics suffers from obesity. Also, when using Glydiab MV 30, the peak of the secretion of insulin is restored.

How much can Glidiab medicine be purchased? At the pharmacy, the price of the medicine is 120-200 rubles. The cost will depend on the number of active component in the tablet. There is a glydiab MB of 30 mg and 80 mg on sale.

Mechanism of action and indication for use

Glideiab MV is a hypoglycemic agent belonging to the group of derivatives of sulfonylurea 2 generations. The medication consists of glyclaside and auxiliary substances. Gliclazide in one tablet contains 80 mg or 30 mg.

How valid active Component drug? Gliclazide with absorption stimulates muscle glycogenecintetase activity and insulin secretion. Also, this substance will potentiate the insulosterectory effect of glucose, and helps to increase the sensitivity of peripheral tissues to insulin.

Moreover, the glyclaside helps reduce the gap between the food intake and the beginning of the active secretion of insulin. If you look at the Glides Instructions for use, it can be found that when using tablets, the peak of hyperglycemia decreases, and the early peak of the insulin secretion is restored.

All these factors affect directly on carbohydrate exchange and microcirculation. If you believe the instructions, the GLIDIAB MV helps reduce the adhesion and platelet aggregation, and at the same time normalize the permeability of the vessels. Simply put, when using tablets, the likelihood of the progression of microthromability and atherosclerosis is significantly reduced.

Also, studies have revealed that the hypoglycemic agent helps to slow down the development of such a complication as Diabesechess retinopathy at the non-proliferative stage. Moreover, when using tablets, GLIDIAB MV can significantly increase the efficiency of diet therapy with overweight patients.

I would like to note that the metabolites of the drug are derived along with the urine unchanged, and together with the feces in the form of metabolites.

Medication Instructions

Sugar level

In what cases is it appropriate to use Glideyab 80 tablets? The instructions say that the remedy is advisable to use in the treatment sugar diabetes 2 types if diet therapy and physical exertion do not help stabilize glucose levels.

In conjunction with other medicines, Glideyab MB is extremely rarely applied. But it should be noted that the hypoglycemic effect of the drug can be increased if, along with medication therapy, it is balanced and play sports.

How to take a medicine? The initial dose is 80 mg. At the same time, the multiplicity of use is 2 times a day - in the morning and in the evening. Take tablets recommended 30-60 minutes before meals.

If the minimum dose of 80 mg does not have hypoglycemic action, then the dosage gradually increases. As a rule, with diabetes 2 types optimal is a dose of 160 mg. The maximum allowable dosage of the medication is 320 mg.

But it must be remembered that with elevated doses, the likelihood of hypoglycemia progression and other complications increase significantly.

Medicinal interaction and contraindications

It must be remembered that a number of drugs are able to increase the hypoglycemic effect of the drug Glideyab MB. So, the instructions are negotiated that the medication needs to be extremely gently combined with histamine H2 receptor blockers, non-steroidal anti-inflammatory drugs, antifungal agents, aPF inhibitors.

Anti-tuberculosis agents, beta-adrenoblays, anticoagulants indirect coumarin series, anabolic steroids, Inhibitors of Mao, Salicylates and others are capable of improving the hypoglycemic effect.

That is why before using Glidiab tablets, you should carefully examine the instructions and take advice from a doctor.

Among the contraindications to the use of tablets can be allocated:

1. Sugar diabetes type 1 insulin-dependent.
2. Diabetic ketoacidosis.
3. Premate or comatose state. Moreover, the strict contraindication is hyperosmolar coma.
4. Leukopenia.
5. Pregnancy period.
6. The lactation period.
7. Heavy liver I. renal failure.
8. States that are accompanied by a violation of the food suction process, and the development of hypoglycemia. These states include intestinal obstruction, stomach paresis and infectious diseases.
9. Allergies to the components of the tablets.
10. The states in which insulin therapy may be required. These states include burns, injuries or surgical interventions.
11. Alcoholism.
12. Fevering syndrome.

Also, the drug must be used with caution to use people suffering from dysfunction thyroid gland.

Reviews and side effects of Glidiaba

What about Glidiab reviews? Diabetics respond about the preparation positively. Many people attract the relatively low cost of the medication, and high rates efficiency.

Moreover, Glidiab, according to diabetics, is good because it rarely causes side effects With low dosages. Even the benefits of the medicine, people belong to the fact that it increases the effectiveness of diet and therapy.

What side effects can cause a hypoglycemic drug? According to the instructions, the medication is able to call:

• Violations in work endocrine system. They are manifested in the form. But it should be noted that this complication occurs only with incorrectly selected dosage of funds.
• Irritability, drowsiness, attacks of aggression, tremor limbs, headache, dizziness, increased fatigue.
• Reducing visual acuity.
• Aphasia.
• Bradycardia.
• Surface breathing.
• Delia.
• Thrombocytopenia, anemia, leukopenia.
• Allergic reactions.
• Failures in work digestive system. A person may have diarrhea, a feeling of gravity in the epigastric area, nausea, anorexia, cholestatic jaundice, an increase in the activity of hepatic transaminases.

Usually, side effects are self-effect after the abolition of the drug and the passage of the corresponding symptomatic therapy.

The best analogue of Glidiaba

What kind of drug glidiab analogs exist? Instead, the means can use various hypoglycemic agents, which are based on metformin hydrochloride. A very effective group analogue is a formatin. This medicine is the best replacement of Glidiaba.

The price of the drug is approximately 180-260 rubles. Datin is produced in the dosage of 500mg, 850 mg and 1 gram. One package contains 60 tablets. The medicine includes metformin hydrochloride, povedium, target, magnesium stearate.

How does the active component of the formulation act? The instructions indicate that metforminum hydrochloride slows down the process of glukegenesis in the liver, and helps to reduce glucose absorption from the intestine.

Also, the current component enhances the peripheral utilization of glucose, and helps increase tissue sensitivity to insulin. At the same time, metformin hydrochloride does not have an action on the process of secretion of insulin by beta cells, due to which the likelihood of hypoglycemia is reduced.

With formulating, you can produce 2 types. Especially often the drug is used when diabetics suffers from obesity and in cases where diet therapy does not help lead glucose indicators in the blood. I would like to note that the drug is often used in conjunction with drugs relating to sulfonylurea derivatives.

How to take formatin? The initial dose is 1000-1700 mg per day. Moreover, the dosage is divided into 2 receptions. Use tablets is better after eating, drinking with plenty of water.

If sugar in the blood does not stabilize, then the dosage is gradually raised to 2-3 grams per day. Maximum allowable daily dose Dutin is 3 grams, no more. But the elderly patients are advised at all to use no more than 1 gram per day.

Contraindications for the use of medication:

1. Allergies to the components.
2. Disorders in the work of the kidneys, in particular renal failure.
3. Acute myocardial infarction phase.
4. Dehydration.
5. Cardiac or respiratory failure.
6. Brain circulation.
7. Chronic alcoholism.
8. Pregnancy and lactation period.
9. States in which there is a need to use insulin. It may be serious injuries, burns or surgical interventions.

Questions and answers

reviews 1.

Release form: solid dosage forms. Pills.

Indications for use:

General characteristics. Structure:

Active ingredient: 30 mg of glyclaside.

Auxiliary substances: hydroxypropylmethylcellulose, microcrystalline cellulose, aerosil, magnesium stearate.

Pharmacological properties:

Pharmacodynamics.GlideiaB ® MV is an oral hypoglycemic drug, generation II sulfonylurea derivatives. Stimulates the secretion of insulin β-cells of the pancreas, enhances the insulosterectory action of glucose, increases the sensitivity of peripheral tissues to insulin. Stimulates the activity of intracellular enzymes - muscle glycogenesis. Reduces the interval from the moment of meals before the start of the secretion of insulin. Restores the early peak of the secretion of insulin (in contrast to other sulfonylurea derivatives, which affect mainly during the second stage of secretion). Reduces the postprandial increase in glucose levels.

In addition to the effect on carbohydrate exchange, it improves microcirculation: reduces the adhesion and platelet aggregation, normalizes the permeability of the vessels, prevents the development of microtrombosis and restores the process of physiological intuboxic fibrinolysis. Reduces the sensitivity of vessel receptors to adrenaline. Slows development at the non-proliferative stage. With on background long use It causes a reliable decline in severity. Does not lead to an increase in body weight, since it has a predominant effect on the early peak of the insulin secretion does not cause hyperinsulinemia; It helps to reduce body weight in obesity patients when complying with the corresponding diet.

Pharmacokinetics.Almost completely absorbed from the gastrointestinal tract after taking inside. Concentration active substance The plasma increases gradually, reaching a maximum after 6-12 hours after taking the drug. Meal does not affect suction. The connection with plasma proteins is approximately 95%. Metabolized in the liver with the formation of inactive metabolites. The half-life is approximately 16 hours. It is removed mainly by the kidneys in the form of metabolites and about 1% of the drug is removed with urine unchanged. Elderly has any significant clinical changes in pharmacokinetics.

Thanks to the features dosage formThe daily reception of a single dose of the drug provides an effective therapeutic plasma glyclaside concentration for 24 hours.

Indications for use:

Diabetes mellitus of type 2 in combination with diet and therapy and moderate physical activity with the ineffectiveness of the latter.

Method of use and dose:

The dose of the drug should be selected individually depending on the clinical manifestations of the disease, the level of glucose is an empty stomach and 2 hours after meals. Typically, the initial daily dose (including for older people over 65) is 30 mg (1 tablet), in the future, if necessary, the dose of the drug is raised with an interval of at least 2 weeks.

Maximum daily dose - 120 mg (4 tablets). The drug is taken inward 1 time per day in the morning, during breakfast.

Glideyab can replace glidiab in doses from 1 to 4 tablets per day.

It can be used in combination with other hypoglycemic agents: biguenides, alpha-glucosidase inhibitors or insulin.

Patients with impaired kidney function from weak to moderate severity (creatinine clearance from 15 to 80 ml / min) is prescribed in the same doses.

Features of application:

Glidiab treatment is carried out in combination with a low-calorie diet with a small carbohydrate content. It is necessary to regularly monitor the content of glucose in an empty stomach and after meals. In the case of surgical interventions or during diabetes decompression, it is necessary to take into account the possibility of using insulin preparations.

It is necessary to prevent patients about the increased risk of occurrence in the case of ethanol, nonsteroidal anti-inflammatory drugs and starvations. In the case of ethanol, the development of disulfira-like syndrome (abdominal pain,) is also possible.

Correction of the dose of the drug during physical or emotional overvoltage, changing the power mode. Particularly sensitive to the action of the hypoglycemic preparations of the face of the elderly; patients not receiving balanced nutrition, weakened patients; Patients suffering from pituitary and adrenal insufficiency.

At the beginning of treatment, during the selection of the dose of patients prone to development, it is not recommended to engage in activities requiring increased attention and speed of psychomotor reactions.

Side effects:

Hypoglycemia (with a disordation of the dosing and inadequate diet):, sense of gravity of the epigastria); - severity decreases when taking a meal; Violations of the liver function (cholestatic jaundice, increasing the activity of "liver" transaminase).

Allergic reactions: itching, maculo-papular rash.

Interaction with other drugs:

Glides enhance the hypoglycemic effect of GLIDIABA inhibitors of angiotensin glossy enzyme (captopril, enalapril), Blocators H2-histamine receptors (cimetidine), antifungal drugs (miconazole, fluconazole), non-steroidal anti-inflammatory drugs (phenylbutan, indomethacin, diclofenac), fibrates (clofibrate, bezafibrat), tivotuberkuleznye drugs (ethionamide), salicylates, indirect anticoagulant coumarin, anabolic steroids, beta-blockers, cyclophosphamide, chloramphenicol, monoamine oxidase inhibitors, sulfonamides prolonged action, fenfluramine, fluoxetine, pentoxifylline, guanethidine, theophylline, drugs that block tubular secretion, reserpine, bromocriptine , Dizeciramide, pyridoxine, allopurinol, ethanol and eta-zero-containing drugs, as well as other hypoglycemic drugs (Akarboz, Biguenides, Insulin).

Weaken Hypoglycemic Action Glides Barbiturates, Glucocorticosteroids, Sympathomimetics (Epinephrine, Clonidine, Rytodrin, Salbutamol, Terbutalin), Phenitoine, Blockers "Slow" Calcium Channels, Carbonic Hexide Inhibitors (Acetazolamide), Tiazide Diuretics, Chlorotalidon, Furosemide, Tamatar, Asparaginase, Baclofen, Danazole , diazoxide, isoniazide, morphine, glucagon, rifampicin, thyroid hormones, lithium salts, high doses - nicotinic acid, chlorpromazine, estrogens and composure of their oral contraceptives.

When interacting with ethanol, the development of a disulfiram-like reaction is possible.

Glyclaside increases the risk of ventricular extrasystole on the background of reception of cardiac glycosides.

Beta adrenoblockers, clonidine, reserpine, guanethidine can mask clinical manifestations hypoglycemia.hypoglycemia (infectious diseases);
- ;
- Pregnancy, breastfeeding period.

With caution (the need for more thorough observation and selection of the dose) is prescribed glidiab in feverish syndrome, alcoholism and thyroid diseases (with a violation of its function).

Overdose:

When overdose is possible, up to development.

Treatment: if the patient is conscious - inside to adopt easily durable carbohydrates (sugar), with a loss of consciousness - intravenously introduce a 40% dextrose solution (glucose), 1-2 mg of glucagon intramuscularly. After restoring the consciousness, the patient needs to be given food, rich in easily digestible carbohydrates to avoid reuse.

Storage conditions:

List B. In the dry, protected from light and inaccessible to children, at a temperature not higher than 25 ° C.Do not use after the period specified on the package.Shelf life - 2 years.

Leave terms:

On prescription

Packaging:

Tablets with a modified release of 30 mg. 10 tablets in contour cellular packaging. 3 or 6 contour cell packages together with the instructions for use are placed in a pack of cardboard.

Description and Instruction: K " Glideyab MV., TBLE 30MG №60 "

Operal hypoglycemic drug

Release form, composition and packaging

Modified Release Tablets white or white with a creamy color tinge, flat-cylindrical, with a chamfer; A marrium is allowed.

Excipients: HalpRellos - 44 mg, microcrystalline cellulose - 123 mg, silicon colloidal dioxide - 1 mg, magnesium stearate - 2 mg.

10 pieces. - Packaging cell contour (3) - packs cardboard.
10 pieces. - Packaging cell contour (6) - packs cardboard.

pharmachologic effect

Oral hypoglycemic drug, derivative of sulfonylurea II generation. Stimulates the secretion of insulin β-cells of the pancreas, enhances the insulosterectory action of glucose, increases the sensitivity of peripheral tissues to insulin. Stimulates the activity of intracellular enzymes - muscle glycogenesis. Reduces the interval from the moment of meals before the start of the secretion of insulin. Restores the early peak of the secretion of insulin (in contrast to other sulfonylurea derivatives, which affect mainly during the second stage of secretion). Reduces the postprandial increase in glucose levels.

In addition to the effect on carbohydrate metabolism, improves microcirculation: reduces the adhesion and platelet aggregation, normalizes the permeability of the vessels, prevents the development of microtrombosis and atherosclerosis, restores the process of physiological intuboxic fibrinolysis. Reduces the sensitivity of vessel receptors to adrenaline.

Slows down the development of diabetic retinopathy at the non-proliferative stage. In diabetic nephropathy, against the background of long-term use, it causes a significant decrease in proteinuria severity.

Glideiab MV does not lead to an increase in body weight, since it has a predominant effect on the early peak of insulin secretion and does not cause hyperinsulinemia; It helps to reduce body weight in obesity patients when complying with the corresponding diet.

Pharmacokinetics

Suction

After the intake, almost completely absorbed from the gastrointestinal tract. The concentration of the active substance in the plasma increases gradually, reaching a maximum after 6-12 hours after taking the drug. Meal does not affect suction.

Due to the features of the dosage form, the daily reception of a single dose of the drug provides an effective therapeutic plasma glyclaside concentration for 24 hours.

Distribution

Binding of plasma proteins is approximately 95%.

Metabolism

Metabolized in the liver with the formation of inactive metabolites.

Election

T 1/2 is approximately 16 hours. It is removed mainly by the kidneys in the form of metabolites and about 1% of the drug is removed with the urine unchanged.

Pharmacokinetics in special clinical cases

Elderly patients do not have any significant clinical changes in pharmacokinetics.

Indications

- type 2 diabetes in combination with diet and therapy and moderate physical activity with the ineffectiveness of the latter.

Contraindications

- type diabetes type 1;

- diabetic ketoacidosis;

- diabetic prema, diabetic coma;

- hyperosmolar coma;

- heavy hepatic and / or renal failure;

- extensive surgical interventions, extensive burns, injuries and other states that require insulin therapy;

- intestinal obstruction;

- stomach paresis;

- states accompanied by a disorder of food suction, the development of hypoglycemia (infectious diseases);

- leukopenia;

- pregnancy;

- lactation period (breastfeeding);

- Increased sensitivity to the components of the drug.

FROM caution The drug should be used (the need for more thorough observation and dose selection) in patients with feverish syndrome, thyroid diseases (with a violation of its function), with alcoholism.

Dosage

The dose of the drug should be selected individually depending on the clinical manifestations of the disease, the level of glucose is an empty stomach and 2 hours after meals.

Initial daily dose (including for older patients older than 65 years) is 30 mg (1 tab.). In the future, if necessary, the dose of the drug is raised with an interval of at least 2 weeks. Maximum daily dose - 120 mg (4 tab.). The drug is taken inside 1 time / day in the morning during breakfast.

Glideyab MV can be replaced with glydiab doses from 1 to 4 tab. / Day.

Glideiab MV can be used in combination with other hypoglycemic agents: biguenides, alpha-glucosidase inhibitors or insulin.

Patients with impaired kidney function from weak to moderate degree (QC from 15 to 80 ml / min) The drug is prescribed in the same doses.

Side effects

From the endocrine system: GUNGLUKUE(with a violation of the dosing and inadequate diet mode) - headache, feeling of fatigue, feeling of hunger, sweating, sharp weakness, aggressiveness, anxiety, irritability, inattention, the inability to focus and slow down reaction, depression, impairment, aphasia, tremor, feeling of helplessness, Sensory disorders, dizziness, loss of self-control, delirium, cramps, hypersmia, loss of consciousness, superficial breathing, bradycardia.

From the digestive system:dyspepsia (nausea, diarrhea, feeling of gravity in epigastria); Anorexia - severity decreases when taking during meals; Violations of the liver function (cholestatic jaundice, increasing the activity of hepatic transaminases).

From the hematopopitation system:anemia, thrombocytopenia, leukopenia.

Allergic reactions:itching, urticaria, maculo-papular rash.

Overdose

Symptoms: It is possible to hypoglycemia, up to the development of the hypoglycemic coma.

Treatment: If the patient is conscious - inside the adoption of easily durable carbohydrates (sugar), with a loss of consciousness - to introduce a 40% solution of dextrose (glucose), to introduce 1-2 mg of glucagon. After restoring the consciousness, the patient needs to give food rich in easily driving carbohydrates to avoid the re-development of hypoglycemia.

Medicinal interaction

The hypoglycemic effect of the GLIDIAB MV is enhanced by simultaneously use with an ACE inhibitors, histamine H 2-receptor (cimetidine), antifungal drugs (miconazole, fluconazole), NSAIDs (phenylbutays, indomethacin, diclofenac), fibrators (clofibrate, bezafibrat), anti-tuberculosis drugs ( ethionamide), salicylates, indirect anticoagulants coumarin, anabolic steroids, beta-blockers, cyclophosphamide, chloramphenicol, MAO inhibitors, sulfonamides prolonged action, with fenfluramine, fluoxetine, pentoxifylline, guanethidine, theophylline, with drugs that block tubular secretion, with reserpine, bromocriptine , disopyramide, pyridoxine, allopurinol, ethanol and ethanol-containing drugs, as well as other hypoglycemic drugs (Akarbazz, Biguenides, insulin).

The hypoglycemic effect of the drug Glideyab MV decreases while using barbiturates, GKS, sympathomimetics (epinephrine, clonidine, riteodrine, salbutin, terbutalin), with phenytio, blocks of slow calcium channels, carboanhydrase inhibitors (acetasolamide), thiazide diuretics, chlorortalidone, furosemide, triamtaren, Asparaginazo, baclophen, danasol, diazoxide, isoniazide, morphine, glucagon, rifampicin, with thyroid hormones, with lithium preparations, with nicotine acid in high doses, with chlorpromazine, estrogens and comprising their oral contraceptives.

When interacting with ethanol, the development of a disulfiram-like reaction is possible.

Glyclaside increases the risk of ventricular extrasystole on the background of reception of cardiac glycosides.

Beta-adrenoblastors, clonidine, reserpine, guanethidine are able to mask clinical manifestations of hypoglycemia.

special instructions

Treatment is carried out in combination with a low-calorie diet with a small content of carbohydrates.

During treatment, an empty stomach glycemic level should be regularly monitored and after meals.

In the case of surgical interventions or during decompensation of diabetes, it is necessary to take into account the possibility of using insulin preparations.

It is necessary to prevent patients about the increased risk of the occurrence of hypoglycemia in the event of ethanol, NSAIDs and starvations. In the case of ethanol, the development of disulfiram-like syndrome (abdominal pain, nausea, vomiting, headache) is also possible.

Correction of the dose of the drug during physical or emotional overvoltage, changing the power mode.

Elderly people's hypoglycemic drugs are particularly sensitive; patients not receiving balanced nutrition; weakened patients; Patients suffering from pituitary and adrenal insufficiency.

Impact on the ability to driving vehicles and control mechanisms

At the beginning of treatment, during the reconnaissance of the dose to patients prone to the development of hypoglycemia, it is not recommended to engage in activities requiring increased attention and speed of psychomotor reactions.

Pregnancy and lactation

The drug is contraindicated to use during pregnancy and during lactation (breastfeeding).